Literature DB >> 26631216

Night-time blood pressure: a role in the prediction and prevention of diabetes?

Martin K Rutter1,2,3.   

Abstract

This commentary discusses and reviews the implications of two studies published in this issue of Diabetologia by Hermida et al (DOIs: 10.1007/s00125-015-3748-8 and 10.1007/s00125-015-3749-7 ) suggesting that high nocturnal blood pressure could have a role in the prediction of diabetes and act as a therapeutic target to prevent diabetes. This overview addresses the clinical implications of this work and new research that is likely to advance this field. It also provides a framework for interpreting claims of causality from observational studies and clinical trials.

Entities:  

Keywords:  Antihypertensive therapy; Chronobiology; Hypertension; Prediction; Prevention; Type 2 diabetes

Mesh:

Substances:

Year:  2015        PMID: 26631216     DOI: 10.1007/s00125-015-3814-2

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  10 in total

1.  THE ENVIRONMENT AND DISEASE: ASSOCIATION OR CAUSATION?

Authors:  A B HILL
Journal:  Proc R Soc Med       Date:  1965-05

2.  Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk.

Authors:  Ramón C Hermida; Diana E Ayala; Artemio Mojón; José R Fernández
Journal:  J Am Coll Cardiol       Date:  2011-09-06       Impact factor: 24.094

Review 3.  Circadian rhythms, sleep, and metabolism.

Authors:  Wenyu Huang; Kathryn Moynihan Ramsey; Biliana Marcheva; Joseph Bass
Journal:  J Clin Invest       Date:  2011-06-01       Impact factor: 14.808

4.  Bedtime ingestion of hypertension medications reduces the risk of new-onset type 2 diabetes: a randomised controlled trial.

Authors:  Ramón C Hermida; Diana E Ayala; Artemio Mojón; José R Fernández
Journal:  Diabetologia       Date:  2015-09-23       Impact factor: 10.122

5.  Sleep-time BP: prognostic marker of type 2 diabetes and therapeutic target for prevention.

Authors:  Ramón C Hermida; Diana E Ayala; Artemio Mojón; José R Fernández
Journal:  Diabetologia       Date:  2015-09-23       Impact factor: 10.122

6.  Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension.

Authors:  Jackie Bosch; Eva Lonn; Janice Pogue; J Malcolm O Arnold; Gilles R Dagenais; Salim Yusuf
Journal:  Circulation       Date:  2005-08-30       Impact factor: 29.690

7.  Efficacy, tolerability and safety of nebivolol in patients with hypertension and diabetes: a post-marketing surveillance study.

Authors:  L M Van Bortel
Journal:  Eur Rev Med Pharmacol Sci       Date:  2010-09       Impact factor: 3.507

8.  Ambulatory blood pressure monitoring in the prediction of cardiovascular events and effects of chronotherapy: rationale and design of the MAPEC study.

Authors:  Ramón C Hermida
Journal:  Chronobiol Int       Date:  2007       Impact factor: 2.877

Review 9.  Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease.

Authors:  Samy I McFarlane; Ashok Kumar; James R Sowers
Journal:  Am J Cardiol       Date:  2003-06-19       Impact factor: 2.778

10.  Telmisartan improves insulin resistance of skeletal muscle through peroxisome proliferator-activated receptor-δ activation.

Authors:  Li Li; Zhidan Luo; Hao Yu; Xiaoli Feng; Peijian Wang; Jian Chen; Yunfei Pu; Yu Zhao; Hongbo He; Jian Zhong; Daoyan Liu; Zhiming Zhu
Journal:  Diabetes       Date:  2012-12-13       Impact factor: 9.461

  10 in total
  2 in total

1.  Elevated asleep BP as predictor of type 2 diabetes and therapeutic target for prevention.

Authors:  Ramón C Hermida; Diana E Ayala; Artemio Mojón; José R Fernández
Journal:  Diabetologia       Date:  2015-12-07       Impact factor: 10.122

2.  Association of mean arterial pressure with 5-year risk of incident diabetes in Chinese adults:a secondary population-based cohort study.

Authors:  Yang Wu; Haofei Hu; Jinlin Cai; Runtian Chen; Xin Zuo; Heng Cheng; Dewen Yan
Journal:  BMJ Open       Date:  2022-09-19       Impact factor: 3.006

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.